Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban

Background  Andexanet alfa (andexanet) is approved for specific anticoagulation reversal in patients with life-threatening or uncontrolled bleeding during treatment with rivaroxaban or apixaban. There is limited experience with andexanet in patients with acute bleeding on edoxaban. Methods  Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Benz, Alexander P., Xu, Lizhen, Eikelboom, John W., Middeldorp, Saskia, Milling, Truman J., Crowther, Mark, Yue, Patrick, Conley, Pamela, Lu, Genmin, Connolly, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251710/
https://www.ncbi.nlm.nih.gov/pubmed/34996121
http://dx.doi.org/10.1055/s-0041-1740180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251710/
https://www.ncbi.nlm.nih.gov/pubmed/34996121
http://dx.doi.org/10.1055/s-0041-1740180

Ejemplares similares